# US 2022/0064736 A1 · Urothelial cancer and methods of detection and targeted therapy

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0064736 A1
- Document ID: US20220064736A1
- Status: Published application
- Kind: A1
- Application number: 17/154,249
- Filed: 2021-01-21
- Published: 2022-03-03
- Earliest claimed: 2015-03-17
- Assignees: The Johns Hopkins University
- Applicants: The Johns Hopkins University
- Inventors: Mohammad O. Hoque; Masamichi Hayashi; Elisa Guida
- Web page: https://patentgrep.com/patent/US20220064736A1

## CPC

- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- A61K 31/7068: having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K 31/711: Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
- C12Q 2600/118: Prognosis of disease development
- C12Q 2600/154: Methylation markers
- C12Q 2600/158: Expression markers
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The invention provides methods for detecting a cellular proliferative disorder (e.g., urothelial cancer) in a subject by assessing the methylation status of the GULP1 promoter in a nucleic acid sample. The methods of the invention are useful for diagnostic, prognostic as well as therapeutic regimen predictions.

## Claims

### Claim 1

A method for detecting a urothelial cell proliferative disorder associated with engulfment adaptor PTB domain containing 1 (GULP1) in a subject comprising:
a) contacting a target nucleic acid in a sample of urothelial tissue or biological fluid from the subject containing urothelial cells with a reagent which detects GULP1, wherein the reagent detects methylation of the promoter region of GULP1 when the target nucleic acid is DNA, and wherein the reagent detects the level of GULP1 RNA when the target nucleic acid is RNA; and
b) detecting GULP1 target nucleic acid, wherein hypermethylation of the promoter of GULP1 DNA, or decreased levels of GULP1 RNA, as compared with the level of GULP1 RNA in a normal cell, is indicative of a urothelial cell proliferative disorder.

### Claim 2 (depends on 1)

The method of claim 1, wherein the subject is a mammalian subject.

### Claim 3 (depends on 1)

The method of claim 1, wherein the biological fluid is selected from the group consisting of a biopsy specimen, a tissue specimen, ejaculate, urine and blood.

### Claim 4 (depends on 1)

The method of claim 1, wherein the reagent which detects methylation of the promoter region of GULP1 is a restriction endonuclease.

### Claim 5 (depends on 4)

The method of claim 4, wherein the restriction endonuclease is methylation sensitive.

### Claim 6 (depends on 5)

The method of claim 5, wherein the restriction endonuclease is selected from the group consisting of MspI, HpaII, BssHII, BstUI and NotI.

### Claim 7 (depends on 1)

The method of claim 1, wherein the reagent is a nucleic acid probe.

### Claim 8 (depends on 7)

The method of claim 7, wherein the nucleic acid probe comprises a nucleic acid sequence as recited in SEQ ID NO: 7 or SEQ ID NO: 13.

### Claim 9 (depends on 7)

The method of claim 7, wherein the probe is detectably labeled.

### Claim 10 (depends on 8)

The method of claim 8, wherein the label is selected from the group consisting of a radioisotope, a bioluminescent compound, a chemiluminescent compound, a fluorescent compound, a metal chelate, and an enzyme.

### Claim 11 (depends on 1)

The method of claim 1, wherein the cell is an epithelial cell.

### Claim 12 (depends on 1)

The method of claim 1, wherein the cell proliferative disorder is carcinoma of the bladder, ureters, kidney, or renal pelvis.

### Claim 13 (depends on 1)

The method of claim 1, wherein the methylation of the promoter region is detected by contacting the target nucleic acid with GULP1 oligonucleotide primers.

### Claim 14 (depends on 12)

The method of claim 12, wherein the primers comprise at least one selected from SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 11 and SEQ ID NO: 12.

### Claim 15 (depends on 1)

The method of claim 1, wherein the detecting comprises contacting the nucleic acids with an agent that modifies nonmethylated cytosine residues, amplifying CpG-containing nucleic acids by means of CpG-specific oligonucleotide primers, wherein the oligonucleotide primers distinguish between modified methylated and nonmethylated nucleic acid, and detecting the methylated CpG-containing promoter region based on the presence or absence of amplification products produced in said amplifying step.

### Claim 16 (depends on 14)

The method of claim 14, wherein the primers comprise at least one selected from SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 11 and SEQ ID NO: 12.

### Claim 17 (depends on 14)

The method of claim 14, wherein the amplifying step comprises a polymerase chain reaction.

### Claim 18 (depends on 14)

The method of claim 14, wherein the modifying agent is bisulfite.

### Claim 19 (depends on 14)

The method of claim 14, wherein cytosine is modified to uracil.

### Claim 20

A method for monitoring the effectiveness of a therapeutic regimen in a subject having a urothelial cell proliferative disorder associated GULP1 comprising:
a) contacting a target nucleic acid in a sample of urothelial tissue or biological fluid from the subject containing urothelial cells with a reagent which detects GULP1, wherein the reagent detects methylation of the promoter region of GULP1 when the target nucleic acid is DNA, and wherein the reagent detects the level of GULP1 RNA when the target nucleic acid is RNA, wherein the contacting of the sample occurs prior to, simultaneously with and/or following a course of treatment; and
b) detecting GULP1 target nucleic acid, wherein a reduction of hypermethylation of the promoter of GULP1 DNA, or increased levels of GULP1 RNA, as compared with the level of GULP1 RNA prior to treatment, is indicative of effectiveness of a therapeutic regimen for treatment of urothelial cell proliferative disorder in the subject.

### Claim 21 (depends on 19)

The method of claim 19, wherein the therapeutic regimen is chemotherapy.

### Claim 22 (depends on 20)

The method of claim 20, wherein the chemotherapy is paclitaxel or cisplatin.

### Claim 23

A method of treating a urothelial cell proliferative disorder associated with GULP1 in a subject comprising:
contacting a GULP1 containing nucleic acid sequence in the subject with an agent that reduces methylation of or demethylates the promoter region of GULP1, wherein the promoter region is hypermethylated as compared with a subject not having a urothelial cell proliferative disorder, thereby increasing expression of the GULP1 gene and ameliorating the symptoms associated with the disorder.

### Claim 24 (depends on 22)

The method of claim 22, wherein the subject is treated with a therapeutic regimen comprising administration of one or more chemotherapeutic agents.

### Claim 25 (depends on 23)

The method of claim 23, wherein the chemotherapeutic agent is administered in combination with a demethylating agent.

### Claim 26 (depends on 22)

The method of claim 22, wherein the demethylating agent is 5-azacytidine, 5-aza-2-deoxycytidine or zebularine.

### Claim 27

A method for providing a prognosis to a subject having a urothelial cell proliferative disorder associated GULP1 comprising:
a) contacting a target nucleic acid in a sample of urothelial tissue or biological fluid from the subject containing urothelial cells with a reagent which detects GULP1, wherein the reagent detects methylation of the promoter region of GULP1 when the target nucleic acid is DNA, and wherein the reagent detects the level of GULP1 RNA when the target nucleic acid is RNA, wherein the contacting of the sample occurs prior to, simultaneously with and/or following a course of treatment;
b) detecting GULP1 target nucleic acid; and
c) providing a prognosis to the subject based on (b), wherein a reduction of hypermethylation of the promoter of GULP1 DNA, or increased levels of GULP1 RNA, as compared with the level of hypermethylation or GULP1 RNA as compared to a reference sample of the subject, is indicative of an increase likelihood of cancer-free survival in the subject.

### Claim 28 (depends on 26)

The method of claim 26, wherein the subject is undergoing a therapeutic regimen.

### Claim 29 (depends on 27)

The method of claim 27, wherein the therapeutic regimen is chemotherapy.

### Claim 30 (depends on 28)

The method of claim 28, wherein the chemotherapy is paclitaxel or cisplatin.

### Claim 31

A method of treating a urothelial cell proliferative disorder associated with GULP1 in a subject comprising:
administering to a subject having or at risk of having the urothelial cell proliferative disorder with an agent that inhibits activation of Nrf2 pathway, thereby treating the urothelial cell proliferative disorder associated with GULP1 in the subject.

### Claim 32 (depends on 30)

The method of claim 30, wherein the agent is administered with a chemotherapeutic agent.

### Claim 33 (depends on 31)

The method of claim 31, wherein the chemotherapeutic agent is paclitaxel or cisplatin.
